October 10, 2005 -- Announcing its Q3 earnings and revenues, biotech heavyweight Genentech reported higher numbers that easily came in above estimates, its own and analysts’. The company announced a 46% improvement in per share profits, which came in at $.35 on a non-GAAP basis, and revenues that were 44% higher than the year earlier at $1.75 billion. There was a lot to like, and the report seemed to calm the fears of investors, which had been growing recently. In after-hours trading, the stock moved almost 6% higher. We take a look...
